Edgewell Personal Care Company (EPC) Earnings Call Transcript & Summary

November 12, 2026

New York Stock Exchange US Consumer Staples Personal Care Products earnings 55 min

Earnings Call Speaker Segments

Chris Gough

executive
#1

Good morning, everyone, and thanks for joining us today for Edgewell's earnings call covering the fourth quarter and fiscal year 2026. Joining me this morning are Rod Little, our President and Chief Executive Officer, and Fran Weissman, our Chief Financial Officer. Rod will open the call, and then he'll pass it to Fran to talk through our 2026 results and the fiscal 2027 outlook. After that, we'll move to Q&A. This call is being recorded, and a replay will be available on our website, www.edgewell.com. During today's call, we may make statements regarding our expectations for future plans and performance. This might cover things like upcoming revenue and profit, outlays on ads and promotions, new product rollouts, spending behind our brands, tech investments, advanced analytics, and AI-powered tools, how we organize and run the business and our operating models, efforts to cut costs and boost productivity, savings and expenses tied to restructuring, how the business is trending and improving its performance, future expansion and value creation, macro and geopolitical matters such as tariff shifts and conflicts or acts of war, changes in our working capital metrics, swings in currency, commodity prices, inflation, upcoming plans for returning capital to shareholders, the divestiture of our feminine care business, and more. Comments of that nature constitute forward-looking statements under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, and they represent our present views regarding future events, plans, or prospects. Statements like these are based on assumptions and involve a range of risks and uncertainties, including the ones outlined under the heading "Risk Factors" in our annual report on Form 10-K for the year ended September 30th, 2025, together with any amendments appearing in our quarterly reports on Form 10-Q filed with the SEC, and in our annual report on Form 10-K for the year ended September 30th, 2026. Those risks could lead our actual results to differ materially from what such forward-looking statements express or imply. We don't undertake any duty to refresh or amend these forward-looking statements because of fresh developments or situations, unless the law says we must. On today's call, we'll cite some non-GAAP financial measures. Those non-GAAP figures aren't put together in line with generally accepted accounting principles. You can find a reconciliation of the non-GAAP financial measures to the closest comparable GAAP measures in the press release we put out earlier today, which sits in the Investor Relations part of our website; we offer this non-GAAP information as an add-on to GAAP-prepared financial performance measures — not as a replacement for them, and not as something better than them. Even so, management feels that these non-GAAP metrics provide investors with useful insight into the fundamental trends of our business and permit more meaningful comparisons of continuing operating results from one period to the next. With that said, I'll now hand the call over to Rod.

Rod Little

executive
#2

Thank you, Chris, and good morning to all of you. At Edgewell, fiscal '26 brought substantial change along with real progress. We're pleased that we met our objectives, and we closed out the year carrying solid momentum throughout the company, helped by organic sales growth returning, better results in North America, gains in productivity, and returns on what we've invested in our priority brands, and we did this while steering through a macro environment that kept shifting, with inflationary pressures mounting and a complicated manufacturing consolidation project in our Wet Shave business. Organic net sales for the fourth quarter rose 3.1%, with both North America and International contributing growth. Gross margin widened by over 500 basis points versus the prior year, and we also posted meaningful increases in adjusted EBITDA and adjusted earnings per share; across the full year, organic sales grew and we raised adjusted earnings per share along with adjusted EBITDA by over 6%. Importantly, no single initiative, customer, or brand drove this improvement. It came from broader progress across the portfolio and shows that the investments we've made and the actions we've taken are making our brands, capabilities, and business performance stronger. There's still work ahead, but fiscal '26 offered mounting evidence that the changes we've made are delivering results. As we enter fiscal '27, we're carrying stronger momentum, and our focus has shifted to expanding that progress. I'd like to walk you through four reasons we feel confident about what's ahead. To begin with, our ability to generate revenue has improved in a fundamental way. During the last several years, we have reinforced the leadership team, increased accountability, and enhanced our capabilities in consumer insights, analytics, revenue growth management, brand building, and customer execution. Those investments sharpen how we plan and distribute resources across the business. Sustained performance ultimately depends on steady execution spanning brands, customers, channels, and markets, and throughout Edgewell we are witnessing more consistency, and witnessing it across a broader scope, than ever before. That gain is likewise visible among major customers and channels—take North America, where Walmart returned to positive territory after shrinking for multiple years, supported by quicker digital expansion and a larger share. Next, our portfolio has become more concentrated as we strengthen our priority brands; now that Feminine Care has been divested and that chapter is behind us, the lineup is leaner, enabling us to channel investment and resources into the brands, categories, and markets with the greatest long-term potential. A common purpose increasingly connects our brands: caring for, safeguarding, and lifting up your skin daily. From Wet Shave—a crucial initial step in the everyday skin care routine—to Sun Care and Grooming, that emphasis guides where we innovate and put our money. During fiscal '26, we placed greater focus on advertising, innovation, and commercial backing for our worldwide priority brands. We achieved encouraging progress across several of our brands. Cremo sustained its robust growth, expanding household penetration and distribution, and demonstrating what results when increased brand support, innovation, and stronger retailer partnerships converge. Hawaiian Tropic built on the momentum generated by its repositioning, its innovation pipeline, and the additional backing behind it. Schick and Billie continue to strengthen via targeted innovation, improved commercial execution, and brand investment; those investments are converting into stronger consumption, greater customer support, and enhanced marketplace performance. Over the entire year, we gained or maintained value share in approximately 70% of our country-category combinations. Looking at the U.S. market in particular, branded aggregate unit share went up during each of the twelve months in the fiscal year. Our approach to investment is shifting as well. During fiscal '26, we redirected commercial spending toward creating durable brand equity, while making substantial reductions in coupons and other near-term promotional efforts. We also boosted A&P dollars by 7% at the same time; for fiscal '27, we anticipate a further meaningful lift in A&P, and we think this will provide steadier, more consistent always-on media backing for our priority brands throughout the year, along with a greater focus on revenue management initiatives that generate stronger ROI. Third, our geographic balance offers us yet another wellspring of strength and opportunity. Roughly half of Edgewell's sales come from outside the U.S., and that business has a long track record of appealing growth. We continue to see meaningful opportunities throughout our international markets, supported by strong brands, favorable positions within categories, and additional room for distribution expansion. In the fourth quarter, International returned to growth, with gains spread broadly across major markets and brands, and for fiscal '27 we anticipate mid-single-digit organic growth; meanwhile, in North America, the adjustments we have implemented are building momentum. Our branded consumption growth outpaced growth for the category overall, total and branded dollar share rose, and we finished the year with solid momentum. All told, we believe that North America and International together can provide a more balanced and durable foundation for growth in the future. Fourth, we are accelerating the reshaping of how we run the business. For Edgewell, fiscal '27 should be another significant year of transition, and we'll concentrate on two things: pushing forward with consolidating the manufacturing footprint for North America Wet Shave, and picking up the pace on the broader overhaul of our operating approach. On Wet Shave, it has turned out to be harder than we expected to bring new capacity online at the same time that our growth profile is accelerating. We have achieved a great deal on this front, but during fiscal '27 our priority will be to carry out the consolidation at a speed that keeps the network stable and customer service consistent. Because of that, the consolidation schedule has shifted by roughly six months versus what we first planned, and we now anticipate the related savings starting in fiscal '28. Our wider transformation goes far past manufacturing and isn't merely an SG&A effort. In fiscal '27, we plan to streamline structures and processes, reinforce procurement and end-to-end planning, improve how resources are allocated, and lean more heavily on technology, advanced analytics, and AI-enabled capabilities. The goal is to increase speed and agility, improve decision-making, and build a structurally lower cost base. Looking ahead to fiscal '27, we expect those savings to fully cover the residual stranded costs from the Feminine Care divestiture — and more. You'll see that show up as reduced SG&A, with the larger piece landing in the back half. This transformation goes beyond simply cutting costs. We're creating the wherewithal to put sustained investment behind our brands and innovation, which is how we drive growth, while at the same time shoring up the business's structural economics and our capacity to weather outside pressures without sacrificing strategic priorities. All of these moves are incorporated into our fiscal '27 plan — which takes me to this year's outlook. As we head into fiscal '27, the results from the second half leave us confident about where the business is going. Organic net sales should rise 1% to 3%, with gains in both North America and International. Our plans feature a significant innovation and brand-building pipeline across our key brands, backed by quicker innovation cycles and stronger commercial activation—steps we believe will keep sharpening our competitive position and help us hit our organic growth targets. We also anticipate adjusted operating profit climbing roughly 10%, fueled by organic sales growth, an improved gross margin, and reduced SG&A stemming from our productivity and transformation efforts. What matters here is that we plan to achieve that growth even as we take on considerable inflation tied to energy and costs from tariffs, and at the same time we'll make another substantial boost to A&P spending in support of our brands. Beneath the operating profit line, our earnings growth should likewise be able to absorb both the expected end of TSA income stemming from the Feminine Care divestiture and a tax rate that will be higher. Our view is that we're heading into fiscal '27 with an organization that is stronger and more focused, along with a rising conviction that the changes we've implemented are building momentum — as shown by better consumption patterns, improved share results across a number of key brands and categories, and greater retailer backing for our plans around innovation and brand investment. These proof points, alongside the wider transformation effort we're pursuing, deepen our conviction that Edgewell can achieve steadier growth and wider margins as time goes on. On that note, I'll hand things over to Fran, who will walk us through the fourth-quarter and full-year results along with the fiscal '27 outlook in more detail. Fran?

Fran Weissman

executive
#3

Thanks, Rod. As Rod explained, the fourth quarter marked another significant step forward in our transformation, with organic net sales growth in both North America and International, along with strong adjusted EBITDA and adjusted EPS growth. I'll now walk you through the quarter in more detail on a continuing operations basis, beginning with the top line, then moving to the P&L, and finishing with our fiscal '27 outlook. Organic net sales increased 3.1% in the quarter, as solid results in Grooming and branded Wet Shave were partly offset by declines in Sun and Skin Care and private label Wet Shave. In North America, organic net sales were up 3.3%, driven by double-digit Grooming growth and mid-single-digit growth in branded Wet Shave, partly offset by declines in Sun Care and private label Wet Shave. International organic net sales rose 3%, with gains across every segment. Wet Shave organic net sales grew 1.6%, as strong growth across the branded portfolio was partly offset by softer private label sales related to the disruption we anticipated from consolidating our supply chain. On an encouraging note, branded Wet Shave growth accelerated in the quarter, with gains in international markets and in North America as well, as better performance across our focus brands and commercial initiatives in the US begin to gain traction. In US razor and blades, category consumption rose 130 basis points. Our US branded share improved in the mass channel, particularly at Walmart and Target, where we've concentrated our resources and commercial investment. Billie continued to perform well, reaching an 11% share overall, with even stronger positions at Walmart and Target. Sun and Skin Care organic net sales rose 6.5%, fueled by strong North America Grooming performance and mid-single-digit international performance. Cremo and Hawaiian Tropic delivered strong results in the quarter, supported by greater distribution, innovation, and brand investment. Cremo grew more than 50% in the quarter, marking its eighth consecutive quarter of greater than 20% growth; in the US, Sun Care category consumption grew approximately 3% in the quarter. Our value share rose 20 basis points, while our unit market share rose 70 basis points, including 280 basis points of share growth in Hawaiian Tropic, partly offset by market share declines in Banana Boat. Looking at the category for the year, consumption grew by 2.5%, and our overall market share was essentially flat and broadly in line with our expectations, while unit share rose by 90 basis points. Moving to the P&L. Adjusted gross margin rose 510 basis points versus the prior year, driven by structural productivity and by lapping transitory costs in last year's fourth quarter. Strong productivity savings, better volume absorption, favorable pricing, and currency more than offset elevated inflation net of tariffs and unfavorable mix. While the improvement was strong, gross margin landed slightly below our expectations, largely because inflation came in higher than anticipated, including rising diesel, freight, and oil prices during the quarter, with those cost pressures adding roughly $0.15 to $0.20 per share, and in a more severe scenario as much as $0.30. Advertising and promotion expenses represented 11.6% of net sales, compared with 9.8% in the prior year, which mirrors the brand investment ramp-up we discussed earlier in the year, including support for Wilkinson Sword, Schick, Billie, Cremo, and the second year of our Hawaiian Tropic campaign. That illustrates our shift toward brand building that is both more sustained and full-funnel. Adjusted SG&A was 20.6% of net sales versus 21.9% a year earlier, driven primarily by lower corporate and people costs this year. Adjusted operating income came to $51.1 million, or 10.6% of net sales, compared with $27.7 million, or 5.9% of net sales, in the prior year, mainly reflecting improved gross margins and reduced SG&A expenses, partially offset by greater A&P investment. GAAP diluted net earnings per share from continuing operations was $0.23 versus $0.26 in the fourth quarter of fiscal '25. Adjusted earnings per share from continuing operations totaled $0.78, compared with $0.52 in the prior-year quarter. Currency benefited adjusted EPS by $0.11 in the quarter, offset by a $0.35 unfavorable income tax headwind. Adjusted EBITDA was $76.8 million, including a $6.3 million favorable currency impact, versus $43 million last year. I'll now turn briefly to our full-year results. Broadly, our full-year results landed as we expected. Organic net sales increased 30 basis points for the year. Our Sun and Skin Care portfolio grew 3%, aided by growth of nearly 13% in our Grooming brands. Sun Care declined slightly, characterized by a weaker than expected international sun season in Europe and Latin America. Wet Shave decreased about 1%, as roughly 2% growth in branded Wet Shave was more than offset by an approximately 10% decline in private label resulting from the supply chain issues we previously flagged. By geography, North America organic net sales grew approximately 40 basis points, mostly on volume. International rose 20 basis points, with net pricing gains partly offset by lower volumes, largely due to a weak sun season in LATAM and Europe plus transitory events such as the Middle East conflict and supply constraints. The adjusted gross margin rate was broadly flat against the prior year. Productivity savings of roughly 230 basis points, favorable pricing, and net currency tailwinds were offset by about 250 basis points of core inflation, including tariffs, along with unfavorable mix. A&P expense was 12.2% as a rate of sale, 60 basis points above the prior year, as we continued stepping up investment behind our brands. Adjusted operating profit declined $11.7 million, or approximately 7%, and adjusted operating margin for the year was 8.1%, down roughly 70 basis points in rate of sale. The drop in adjusted operating income margin stemmed mainly from the higher brand marketing investment, increased SG&A expense, and modest gross margin declines. It's worth noting that Fem Care divestiture stranded costs show up in both operating profit and EBITDA, whereas the TSA income offset appears only in EBITDA. Adjusted EPS from continuing operations was $1.93, compared with $1.81 in the same period last year. Currency provided a 20-cent favorable boost to adjusted EPS for the year, though a 30-cent unfavorable income tax headwind offset that. Adjusted EBITDA came to $254.5 million, which includes an $11.5 million favorable currency impact, against $239.7 million in the prior year. Net cash provided by operating activities for fiscal '26 was about $50 million, compared with roughly $118 million last year, largely reflecting lower earnings along with the cash flow headwinds associated with the Fem Care divestiture. Note that cash flow is presented on a consolidated basis, covering both continuing and discontinued operations. Adjusted free cash flow was $86 million, a number that adjusts for one-time cash flow impacts tied directly to the Fem divestiture, among them tax on proceeds, working capital, and deal-related fees and expenses. Adjusted net debt leverage was 3.4. We maintained our quarterly dividend payout, declaring 15 cents per share for the fourth quarter, and returned roughly $7 million to shareholders through dividends. Turning to our outlook for fiscal '27. As Rod noted, the progress made in the second half gives us confidence in the business's underlying trajectory as we enter fiscal '27, even as we navigate a dynamic external environment.

Fran Weissman

executive
#4

That guidance rests on the momentum we have, and it assumes organic net sales will rise in each segment and every market, gross margin will expand, and adjusted earnings will grow. We plan to do that while committing still more funding to our focus brands, with A&P up and sustained across the entire year. Accelerating the transformation of our operating model will reduce SG&A, and those savings will more than cover the stranded costs that remain from the Fem Care divestiture while also funding brand investment and earnings growth. Our outlook also takes in elevated inflation and the expiry of income from the Fem Transition Service Agreement, which shows how solid the underlying plan is. Now the details for fiscal '27. Organic net sales growth should come in at 1% to 3%, with gains in both International and North America. Currency is likely to be a headwind of roughly 60 basis points on reported net sales; for the first quarter, organic net sales should be flat to down about 1%; that mirrors an expected timing shift of North America Sun Care sell-in from Q1 into Q2, plus continued pressure in private label linked to the Wet Shave consolidation issues we discussed all through fiscal '26; capacity-related pressure should peak in Q1, ease considerably in Q2, and private label should return to growth in the second half. On adjusted gross margin, we anticipate about 60 basis points of expansion versus last year in fiscal '27. That gain will stem from productivity, procurement, and transformation savings, our strengthening revenue management initiatives, and modest price increases. Those benefits will be partly offset by higher costs across the supply chain, including substantial energy-related inflation. Our oil outlook uses the EIA outlook, with prices expected to begin stabilizing as the year progresses. On phasing, gross margin rate should be roughly flat in the first half, with expansion building in the second half; the inflation impact should be fairly consistent through the year, while productivity, volume absorption, and strategic revenue management benefits build as the year goes on. A&P should rise in both dollars and rate, up about 80 basis points to approximately 13% of net sales. That increase should be concentrated in the first half, including a step-up in Q1 to approximately 14% of net sales, as we shift to an always-on investment cadence behind our brands. Adjusted SG&A should improve by 90 basis points as a rate of sales, as savings from our transformation initiatives more than offset the stranded costs remaining from the Fem Care divestiture. Those savings should build through the year, contributing more in the second half. Adjusted operating profit margin is expected to rise approximately 70 basis points, as gross margin expansion and lower SG&A more than offset higher A&P investment. Adjusted EPS is expected in the range of $1.85 to $2.15 per share, growing approximately 3.5% at the midpoint of the range, with the components of that growth including $0.03 and $0.17. This outlook factors in about 20 cents of expected headwinds below operating profit, and that number consists of 17 cents related to the TSA income expiring plus 3 cents from a higher effective tax rate of roughly 24%, which is up around a point from fiscal '26. For fiscal '27, adjusted EBITDA is expected to come in at $250 million to $270 million, which works out to about 2% growth over the prior year at the midpoint of the range, and the loss of roughly $11 million in TSA income is absorbed within that range. On phasing, we expect two-thirds of adjusted EBITDA and about 80% of adjusted EPS to be generated in the second half. That mirrors the expected concentration of our A&P increase in the first half, along with transformation savings that build up as the year goes on. For Q1, adjusted EPS is expected to be below the prior year, mainly because of the Q1 A&P step-up and higher SG&A expenses. Adjusted free cash flow for the year is expected to fall in the range of $100 million to $120 million, and that number includes the cash impact of restructuring-related costs while adjusting for working capital changes and other items tied to the Fem Care divestiture. As we accelerate the transformation of our operating model, we expect to incur restructuring and related charges of about $55 million in fiscal '27. Our capital allocation priorities remain the same. Near term, we remain focused on lowering leverage while continuing our quarterly dividend and share repurchases, which will primarily offset dilution. For the specific guidance ranges, please see the press release issued earlier today. With that, I'll turn the call over to the operator for Q&A.

Nick Modi

analyst
#5

It’s not clear what the outlook is, so I’d really appreciate your take on how you’re sizing up the consumer and what assumptions sit behind that guidance. Also, what we’ve observed in the past is that whenever a business moves from struggling to getting momentum back, the trade gets quite energized. I was just hoping you could share some perspective on shelf space and what your thinking is for that next year. Thanks.

Chris Gough

executive
#6

Hey Nick, it's Chris here. You dropped out right at the start of the question; the second part came through, but we didn't get the first, so could you say it again, please.

Nick Modi

analyst
#7

Oh, my apologies. Of course. Regarding the consumer backdrop, what are you factoring into your assumptions for the year? Thank you.

Rod Little

executive
#8

Morning, Nick. I’ll address those one at a time. So, our assumption is that the categories we compete in will perform roughly in line with how they’ve done across the past 6 to 12 months. If you look at aggregate category growth for the past 13-week, 26-week and 52-week periods, it’s been fairly steady. Volume trends may have softened a little, yet at the price level things are very steady, and that is what we’re planning for going forward. We expect low growth in the categories, with continued relative outperformance if we reach the top end of our range. At the midpoint, the implication is essentially that we hold share, which is broadly how we’re looking at it, and we’re being very careful about the price components. We will push hard on revenue management, price per unit and price per pack, since the pricing environment in our categories remains difficult. Consumers are stretched and highly price-sensitive, and retailers, as they compete with one another, are effectively not open to price. Overall, what we’ve observed during the last 6 to 12 months is what I’d say we expect to continue, and that is what our guidance incorporates. On your second point, you’re absolutely right: once you start winning with consumers and shoppers, retailers view you differently and begin supporting you in different ways. We’ve been on a 1- to 2-year journey to strengthen our standing with retailers and improve our brand support. We now spend 3 points of sales more on marketing and advertising support than we did in fiscal ’24, when we were at about a 10% rate of sale. As Fran said earlier, our guide outlook contemplates 13% of sales. Retailers can see that consumers are responding to that, and what happened in the year just finished, together with what we believe will keep happening as we move into ’27, is net positive distribution outcomes: more space, higher quality, better shelf positioning, more endcap and off-aisle displays. That read is global, not just a US view, and it gives us confidence going into this year that retailers recognize the progress we’re making and are rewarding us with those kinds of outcomes.

Nick Modi

analyst
#9

Excellent. Thank you so much. I'll pass it on.

Rod Little

executive
#10

Thanks, Nick.

Chris Gough

executive
#11

Thanks, Nick. Operator, next question, please.

Peter Grom

analyst
#12

Great, thanks. Morning, everyone. Rod, I'd like to focus in on the long-term margin opportunity specifically. You've mentioned the different things you're doing in SG&A, plant consolidation, and I realize there are plenty of moving parts and timing issues involved. Could you perhaps walk through how you're thinking about the long-term margin opportunity? Obviously you're looking at another strong year even with plenty of external headwinds. From what you've said, it sounds like there's simply more ahead. I'm just wondering whether you could offer some perspective on that as we think about perhaps '28 and beyond.

Rod Little

executive
#13

Morning, Peter. Well, we're in a structurally favorable cycle when it comes to gross margin development and our ability to accrete and expand gross margin from here. Apologies if there's some background noise. Three levers drive the margin play. Number one is pricing, revenue management, and we believe we have a very solid plan when we consider every component of pricing. That may involve less change to list price for the consumer and more attention to all of our spending between gross and net sales, optimizing it so it works harder on our behalf. Another pricing element worth highlighting is that as our brand health strengthens, with better consumer metrics, higher household penetration, stronger resonance of the content our teams create and place before consumers, and better market share outcomes, with 70% of our category-country combinations either holding or growing share, that too creates an opportunity on the price line that honestly we simply lacked 1 or 2 years ago. Price is a major lever. Cost of goods is a major lever too. When you examine the cost of goods line, the shave consolidation is a significant component; all of that lies ahead of us and is still to come. Then the last piece is the leverage we ought to gain on the SG&A line, not just through our capacity to manage that line and gain leverage on scale as we grow, but also through some absolute cost reductions, as reflected in our implied guide for fiscal '27. All three levers will play a part. We won't call out a long-term target. We do have one in mind that we're pursuing. Once again, I have plenty of confidence that we can build margin from here and that we have levers to offset things if we encounter higher inflation or tariff costs from here.

Peter Grom

analyst
#14

That's really useful. Then perhaps, as a follow-up and a bit more near term, when you talk about substantial inflation, could you break out specifically what you're anticipating or building into the guidance for this year?

Fran Weissman

executive
#15

When we consider inflation and examine how we're exiting in Q4, we have a mix of core inflation, the annualization of tariffs, and oil and commodity prices rising more in line with what we're seeing at present for oil prices and with what the EIA outlook has shown, which is roughly around the mid-80s. We would anticipate greater pressures during the first half, with easing in the second half. As we cycle next year, overall inflation comes to about 300 basis points when we look across all of those components. What I think offsets that is well over 250 basis points of productivity and volume absorption, since as we raise our overall units, we're achieving better capacity against our plants, and we're strongly focused on price and revenue management, which will help offset and balance the overall gross margin profile and place us where we're expanding year-over-year.

Peter Grom

analyst
#16

Wonderful. Thanks to the two of you. I will make sure that gets shared.

Fran Weissman

executive
#17

Thank you, Peter.

Chris Carey

analyst
#18

Hey everyone, appreciate the question. So to start with the private label situation, could you give us a feel for how that headwind developed across fiscal '26, maybe some sense of the quarterly pattern and how big an impact it had? I believe I caught a way to frame it for the full year, but I'd like to understand how it played out as the year went on. And then, what kind of visibility do you have on that supply constraint easing, and give us a sense of how that will look, North America versus International? Then I've got a follow-up.

Rod Little

executive
#19

Morning, Chris. Well, the private label dynamics and the supply constraints are mostly being driven by the new plant consolidation work we're doing in Wet Shave. Again, strategically it's a really important project for us; it's a huge cost unlock, scale, automation, all those good things that come with it over time. We're early in that journey, about 50% through the project of four plants consolidated into one new greenfield site. When it comes to the fiscal '26 plan, we were cutting orders from the start of the year in North American private label. For context, in the year just completed, '26, private label was down roughly 10% in shave, branded up roughly 2%. That was the drag, and it was supply constrained, which drove that far more than consumer demand or impact. What you see though is we did recover some of that decline through growth in branded; we were cutting in North America the whole year from the beginning. As we discussed, we trimmed the tail, exited low-gross-margin customers over the year to concentrate on our most profitable customers. That's actually a plus for us going forward. When we got into Q3, that's really when it peaked, when we were cutting in Europe as well, and you saw that in our reported results. The good news as we exit the year is that we're moving up the curve on production output. Fewer lines are constrained. You saw the improvement in Q4, especially in the European business where we returned to growth as that production output came online, and we have good line of sight to what we build this year, with quarter one really the quarter most impacted by that constraint. Once we get into Q2, 3, 4, we lap it, and we actually have growth planned in the back half of '27 on the private brands business. We know where we are; we don't love where we are, but we feel good about where we are. Another point worth making as we move ahead is that the branded business has performed very well, so once we reach the second half of the year and this gets unlocked, I believe we'll be in a solid position on the shave portfolio. The last element here is that we've taken everything we learned from the first two sites, which are obviously now consolidated, and applied it to the final two sites remaining. The transfer of those last two sites is already underway, so that work is progressing. I think we've phased the savings appropriately out of fiscal '27 and into our fiscal '28. The guidance we've provided includes no savings from that program, and those savings will then start to arrive in fiscal '28 for you.

Chris Carey

analyst
#20

Okay. All right. Great. On how sustainable the faster-growing parts of the portfolio are, Grooming included, could you give us a feel for what the pipeline looks like over the near term? And maybe also, if you would, touch on our two biggest brands in Sun Care and how you expect some of that share to play out going into next year, since momentum for one is quite a bit stronger than the other at the moment. That's all from me. Thanks.

Rod Little

executive
#21

Yeah. When it comes to the faster-growth areas, Cremo is out in front, 50% in the quarter, and over the past eight quarters growth has been 20-plus percent. That brand is accelerating. Innovation and new product launches are driving it, along with better distribution, and the outcomes are ones we do expect to keep going. Strength in that brand is now broad-based, not just in beard care, which is growing within a declining segment and was the brand's heritage when we acquired it, but body washes in particular are fast-growing, and more recently we've added antiperspirant deodorant as we widen the range there. We see Cremo's growth as very durable, with a lot more to come. Bulldog is the other brand I'd highlight, fast-growing, and it has done really well for us across the European markets. Again, great innovation, a really nice pipeline, and a really tight focus on the marketing message and the target we're going after there. Hawaiian Tropic and Banana Boat had very different outcomes in fiscal '26. Hawaiian Tropic gained almost 300 basis points of share across the year, with household penetration rising and all the consumer metrics where you want them, as we put investment behind that business in the year past. Looking to '27, we think we'll keep having good momentum on Hawaiian Tropic. The big news is going to be on Banana Boat, which we expect to move from share decline into more of a share-hold position, as we relaunched the brand with brand-new packaging, restaged. Retailers and consumers have reacted very positively to that, a new pack campaign, great content with that. I think Banana Boat, which was a leaky bucket in '26, will not be as we look to '27.

Chris Gough

executive
#22

Thanks, Chris.

Chris Carey

analyst
#23

All right, thanks.

Chris Gough

executive
#24

Operator, could we take the next question, please.

Susan Anderson

analyst
#25

Hi there. Good morning. I appreciate you taking my questions. So I suppose this is somewhat a follow-up on that point — it sounds like Banana Boat is being relaunched, but beyond that, I wonder whether any new innovation is on the way across the portfolio, be it Sun and Skin or Shave, and if you could speak to that for 2027. And then, any refreshed thinking on M&A that might bring some faster-growing brands into your portfolio within your core areas? Thank you.

Rod Little

executive
#26

Good morning, Susan. Innovation is rolling out broadly across the portfolio. I won't get into specifics by naming particular products or the changes we're making, but a whole suite of innovation is coming across Cremo and our Grooming brands. The same holds for our Sun Care brands. Under Hawaiian Tropic and Banana Boat both, we have new formulation launches arriving next year. What I haven't yet discussed is Shave. We have some genuinely compelling innovation; we've announced it and it has already launched — in fact it just launched last month in Japan, Schick First Acne Safe. This builds on our Schick First Tokyo launch, which came out more than a year ago; now we're arriving with an upgrade and an addition to that line featuring a razor that is the safest razor ever brought to market and performs well on acne-prone skin. That just launched, and we have solid investment behind it to drive it, along with really good distribution outcomes behind it as we look across Japan and then more broadly across Asia. Domestically in the US, we have launches of certain technologies and brands we've had in other places, mainly on Schick as we look at what we're launching here. Billie will be the focal point of new innovation we're bringing to market this year on the Billie brand. Again, I won't be specific about what that is, but as we get into the spring planogram resets, you'll see it roll out. It's the biggest innovation we've had on the Billie line since we acquired it a few years ago. We feel good that the broad-based innovation we have should, year-over-year, be accretive to our growth rate as we look at the total innovation plot for the year.

Susan Anderson

analyst
#27

Great. So turning to Sun and Skin, it sounds like Grooming played a major role there. I may have missed this, but could you discuss how Sun performed in North America and Internationally? I believe the sell-out, at least based on Circana data for North America, has been quite robust, so I'm just wondering how sell-in went for you and how retail inventory stood at the end of the season. Thanks.

Rod Little

executive
#28

Yeah. To begin, I'll give an overview, and then, Fran, you can add. What I'd say is that internationally, Sun Care was soft, mainly because weather in Europe and Latin America wasn't great. Domestically in the US, the Sun Care category was merely okay; it was quite wet. It did see growth, and penetration is better. From a broader category weather standpoint, I'd characterize it as an average to below-average year that we're comping against.

Fran Weissman

executive
#29

Susan, what I’d say is that with US Sun, we largely achieved low-single-digit growth, exactly as we planned, with share broadly flat, and for the year we gained 90 basis points. Naturally, there are pluses and minuses across the quarters, but Q4 consumption was really strong, with quarterly share up roughly 70 basis points. On retail inventory, we feel very good that consumption has been solid and our sell-in has been solid too. As Rod explained, the majority of the softness we saw in Sun came from weather-affected regions in LATAM and Europe, yet we’re still very confident in how we performed in the US, and that has met expectations.

Susan Anderson

analyst
#30

Great, thank you very much. Best of luck in fiscal '27.

Rod Little

executive
#31

Thanks, Susan.

Chris Gough

executive
#32

Operator, let's take the next question.

Olivia Tong

analyst
#33

Thanks, and good morning. I'd like you to compare how we did this year in Shave against Sun and Skin, and then share where you see the larger rate of change coming next year. On Sun Care specifically, Hawaiian Tropic has clearly made great progress, and it sounds like some activity is planned for Banana Boat in fiscal '27. How are you thinking about the rate of change there, given that this year was unfortunately held back somewhat by the weather? There are also formulation changes coming across the category in '27. How are you planning for that? Thanks.

Fran Weissman

executive
#34

Thank you, Olivia. I'll address your questions in two sections. First, to close out the Sun season this year for Hawaiian Tropic and Banana Boat: we had always expected Banana Boat to lose some share, and our outlook accounted for that. On the whole, share performance came in as we anticipated — Hawaiian Tropic gained roughly 280 basis points, Banana Boat saw some declines, yet unit share overall rose about 90 basis points. Looking at how we delivered the year, we got back to top-line growth, and that showed up consistently in branded Wet Shave, which remains at low-single-digit growth. On the Sun side, Grooming posted high-single-digit growth. Looking at how each segment did, branded products turned in a solid showing — in the US specifically, the core brands we've concentrated on rose roughly 4%. North America has settled down, and those core brands are landing right where we expected, climbing by a low single-digit rate, which is feeding into the branded share trend overall — that's up about 40. The money we're putting behind these brands feels well spent, and the evidence keeps building that brand equity is getting stronger. Going into '27, we expect that momentum to carry on. We expect continued expansion in branded Wet Shave, and in those markets we will keep defending and building our share. Sun and Skin are likewise set to keep growing. That comes from gains across both Sun and Grooming, with Grooming projected at roughly high single digits. When we look at the full-year growth picture for next year, private label is really the one soft spot. We're anticipating some contraction there during the first half, with a return to growth afterward. That's what drives the shape of our phasing—first half sitting at the bottom of the range, second half at the top. It also reinforces what Rod mentioned earlier about distribution, since much of our innovation will be scaling up during the back half of the year.

Rod Little

executive
#35

Olivia, let me just add to that and sum it up; the two of us have known each other for some time now. What is different as we look toward '27 compared with any point in the recent past is how deep and how broad our growth profile is. Grooming is expanding quickly. Next year, Sun, Skin, and Shave will each be growing. Right, that is what we project. Every segment of ours is growing. Our spread is now very balanced between International and North America, and both of those are growing. Look at brands, at segments, at geographies — all of it is growing, and that is the difference; we have eliminated the leaky buckets, partly through M&A choices and largely through sheer improvement in how we run our brands and in the teams running them; that is the part that looks different. From here, everything contributes to growth.

Olivia Tong

analyst
#36

Understood, thanks. Could I also ask something on the advertising side? You talked about 13% for next year. Over the longer term, what's the appropriate amount of ad spend as a proportion of your sales? Is 13% roughly where you expect it to sit, or could it climb even beyond that as you put more emphasis on branded initiatives?

Fran Weissman

executive
#37

Thanks, Olivia. When we consider A&P spend in total, we've deliberately been stepping it up during the past couple of years so that we deliver sustainable brand equity across our brands. That increase has been deliberate and substantial over the last 18 months; in half two, we raised A&P investment disproportionately to really underpin that return to growth trajectory; now, as we go into fiscal '27, you'll see disproportionately bigger A&P increases in the first half, since that has been a deliberate choice to ensure that all year long we have an always-on media approach across every one of our brands. As we exit fiscal '27 into '28, we'll see improved leverage from our A&P spend, when we'll have consistency in growth and the step-up we've seen over the last 2 years will begin to moderate. When we think about the absolute rate of sales, an absolute target isn't what we're aiming for. We're making sure we're getting better ROI across these brands, and our focus is on investing in the right aspects for brand building and a better balance between our coupon spend and our commercial investment. I think the last piece you'll see is that some of the gross margin improvement we've seen has come from an intentional focus on revenue management. We've discussed throughout the year how we're balancing more around lowering our coupon spend and shifting that spend to upper-funnel activity. We've seen that hold traction. We've seen that improve our brand equity scores and our household penetration. I think what you'll also keep seeing as we move forward is simply a better balance of commercial investment between point of purchase and also brand building and upper funnel.

Olivia Tong

analyst
#38

All right, thanks.

Rod Little

executive
#39

Thanks, Olivia. Operator, could we take the next question, please?

Rod Little

executive
#40

Okay, thanks everyone. So, we closed the fourth quarter on a strong note; the plan and outlook we have for the coming year are balanced and carry forward the momentum we had as we left last year. To wrap up, we have a genuinely solid team, with stronger capabilities and a stronger leadership profile running the business, and I really want to express my appreciation to the team for what they've put in, since that is now beginning to be reflected in the results. Thanks, and we'll speak again in early February when the Q1 report comes out.

Operator

operator
#41

That brings this conference to a close. We appreciate your participation in today's presentation. You're welcome to disconnect at this time.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Edgewell Personal Care Company transcript — plus 133,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Edgewell Personal Care Company earnings transcripts and 133,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Edgewell Personal Care Company or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.